Analysts predict that Fluidigm Co. (NASDAQ:FLDM) will post $30.19 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Fluidigm’s earnings, with estimates ranging from $29.80 million to $30.46 million. Fluidigm posted sales of $26.43 million during the same quarter last year, which suggests a positive year over year growth rate of 14.2%. The company is expected to report its next earnings results after the market closes on Thursday, August 1st.
According to Zacks, analysts expect that Fluidigm will report full-year sales of $127.90 million for the current year, with estimates ranging from $126.90 million to $129.70 million. For the next financial year, analysts expect that the firm will post sales of $141.80 million, with estimates ranging from $139.10 million to $143.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Fluidigm.
Fluidigm (NASDAQ:FLDM) last issued its quarterly earnings results on Thursday, May 2nd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.30). Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The business had revenue of $30.10 million for the quarter, compared to analysts’ expectations of $29.18 million. Fluidigm’s quarterly revenue was up 19.4% on a year-over-year basis.
In other Fluidigm news, insider Levin Easterly Partners Llc sold 217,148 shares of the firm’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $12.28, for a total transaction of $2,666,577.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Nicolas Barthelemy sold 5,100 shares of the firm’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $12.43, for a total transaction of $63,393.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 784,571 shares of company stock valued at $9,449,631. 2.20% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA increased its stake in Fluidigm by 3,543.1% during the 1st quarter. BNP Paribas Arbitrage SA now owns 6,849 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 6,661 shares in the last quarter. Metropolitan Life Insurance Co NY bought a new stake in shares of Fluidigm in the first quarter worth approximately $151,000. United Services Automobile Association bought a new stake in shares of Fluidigm in the fourth quarter worth approximately $102,000. Marshall Wace North America L.P. bought a new stake in shares of Fluidigm in the first quarter worth approximately $159,000. Finally, Ibex Investors LLC bought a new stake in shares of Fluidigm in the first quarter worth approximately $175,000. Institutional investors and hedge funds own 92.64% of the company’s stock.
NASDAQ FLDM remained flat at $$11.49 during trading hours on Friday. 439,323 shares of the company were exchanged, compared to its average volume of 1,014,721. Fluidigm has a one year low of $5.50 and a one year high of $14.90. The firm has a market capitalization of $793.04 million, a P/E ratio of -14.36 and a beta of 2.15. The business’s 50-day moving average is $12.12. The company has a current ratio of 3.26, a quick ratio of 2.86 and a debt-to-equity ratio of 0.30.
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.
Featured Article: What is the QQQ ETF?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.